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Introduction
Direct oral anticoagulants (DOACs) have emerged as a convenient and effective prophylaxis regimen against venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) occurring after total hip and knee replacement (THR and TKR). For THR and TKR, The American College of Chest Physicians (ACCP) has traditionally recommended higher potency agents (e.g. fondaparinux, low-molecularweight heparin and vitamin K antagonists titrated to INR 2-3) and recommended against aspirin [1] . More recently, the organization has expanded the choice to include aspirin and DOACs in addition to the previously recommended agents, given there is no clear favorite among the above regimens [2] . They do make a suggestion (not a recommendation) for use of low-molecular-weight heparin (LMWH) based on its longer safety record. The ACCP guidelines are based on trials directly comparing one prophylaxis option against another. Additional information about the comparative effectiveness of two treatments is available through simultaneous comparison of all regimens using indirect comparisons [3, 4] . Using a network meta-analysis approach, we simultaneously measured the efficacy in preventing VTE and safety in avoiding hemorrhage for 12 important prophylaxis strategies.
Methods
IRB approval and patient consent were not required for this study.
Data sources and study selection
We searched OVID Medline, the Cochrane Library and Clinicaltrials.gov (January 1990 until June 2016) to identify randomized controlled trials (RCTs) comparing VTE prophylaxis options (see below) in patients undergoing TKR or THR surgery. We also manually searched the bibliographies of included studies, guidelines [2, 5] and existing meta-analyses [6, 7] per usual practice [8] . We did not search before 1990, given changes in practice patterns, including routine use of mechanical prophylaxis and early mobilization after 1990 (see Table 1 for search strategy). We did not search EMBASE and limited inclusion to English language studies, consistent with recent data indicating the lack of impact from searching EMBASE [9] and the Agency for Healthcare Research and Quality's suggestion of lack of compelling evidence for inclusion of non-English language systematic reviews [10] . Prophylaxis strategies we included are: (i) fondaparinux, (ii) direct thrombin inhibitors, (iii) direct oral Xa inhibitors (direct oral factor Xa inhibitors), (iv) lowmolecular-weight heparin (LMWH) at twice daily dosing (LMWH High), (v) LMWH at once daily dosing (enoxaparin 40 mg or dalteparin 5000 IU once a day; LMWH Low), (vi) vitamin K antagonists (VKAs) titrated to an International Normalized Ratio (INR) 2-3, (vii) VKA titrated to INR < 2, (viii) unfractionated heparin, (ix) aspirin, (x) dynamic mechanical options (including intermittent pneumatic compression of leg or foot), (xi) static mechanical options (i.e. compression stockings), and (xii) no antithrombotic or mechanical compression.
Data extraction and quality assessment
For each included study, two reviewers extracted information about the publication, study design, population intervention outcomes and methodological quality items. Reviewers resolved discrepancies through discussion. We also contacted study authors for missing information.
For the total DVT (asymptomatic + symptomatic) outcome, we extracted the number of events diagnosed before or at the time of mandatory surveillance radiography (venography or ultrasound). We don't report the DVT rates after surveillance because clinicians caring for study subjects invariably treated asymptomatic DVT diagnosed by surveillance. In cases in which there was no surveillance radiography, we extracted the number of DVTs occurring closest to day 11 which is approximately when surveillance radiography occurred in the majority of studies.
For major hemorrhage, we extracted the rate of events as defined by study authors occurring up to and including the day of surveillance for the total DVT outcome. Definitions of major hemorrhage varied across studies; most study authors utilized the International Society of Thrombosis and Haematosis 2005 definition [11] . We also performed subset analysis to examine the influence of the definition of hemorrhage.
Data synthesis and analysis
For the main analysis, we conducted network meta-analyses under a Bayesian framework. A network meta-analysis combines direct evidence (i.e. from head-to-head comparisons) and indirect evidence (i.e. from comparisons made through other reference interventions). Combining the direct and indirect evidence improves precision of estimates and also provides estimates for all pairwise comparisons, including those missing from the direct evidence. For the outcomes of interest in this project, the network metaanalysis model corresponds to a generalized linear mixed model with a logit link. We included random effects on the treatment parameters, which allowed each study to have a different but related treatment effect estimate. The between-study variance (heterogeneity) was assumed to be constant across all treatment comparisons. We used noninformative prior distributions for the model parameters.
As stated earlier, the main analyses combine direct and indirect evidence under the assumption that these two independent lines of evidence are consistent (i.e. agree between them). In order to examine this assumption of consistency between direct and indirect comparisons, we examined whether a variant network meta-analysis model that allows direct and indirect evidence to disagree fits the data better than our main analysis. If the inconsistency model fits the data better, it is an indication against including indirect data in the estimation of treatment effects. Secondly, we conducted separate traditional random effect meta-analyses for all available direct comparisons and compared these with the network results. (Technical report available upon request for further details.)
In the secondary analyses, we compared 11 prophylaxis options with LMWH Low for the outcomes of symptomatic DVT and non-fatal PE. We also generated a 12 9 12 table with each comparator sequentially occupying the role as the reference option. Next, we re-measured individual comparisons between prophylaxis options in subsets of studies containing a certain characteristic (e.g. studies with appropriate randomization, non-industry sponsorship, etc).
For both main and secondary outcomes, we also calculated the predicted event rate for each of these prophylaxis options. More specifically, we converted the odds ratios (ORs) generated from our network meta-analyses to risk ratios. This conversion requires establishing a baseline risk for each outcome for the reference prophylaxis option of LMWH Low. To estimate baseline risk, we selected the larger, more representative studies within the set of studies examining LMWH Low [12, 13] .
We performed all analyses in computer language R and Bayesian software JAGS [14, 15] .
For more information on included studies and data abstraction, please see online Supporting Tables S1 and S2.
Results
We identified 94 studies that met all of our inclusion criteria (see Fig. 1 ). In the majority of studies (90%), study subjects had a mean age of greater than 60 years. Fifty-seven per cent of studies had industry sponsorship (industry studies). In terms of quality, the majority of studies had appropriate randomization, appropriate description of withdrawal and dropouts and low loss to follow-up ( Table 2 and Table S1 for further details). From the two largest studies including LMWH Low [12, 13] , we identified the following baseline risk ranges for each outcome (expressed in the following list as number of events out of 1000): total DVT, 100-300; major hemorrhage, 2.5-30; symptomatic DVT, 2.5-20; non-fatal, PE 1-3.
We found that LMWH Low was the most common comparator in our network ( Fig. 2 for topologies of all comparisons). For DVT, relative to LMWH Low, direct oral Xa inhibitors performed best, with OR 0.45 and 95% confidence interval (CI) 0.35-0.57, translating to 53-139 fewer VTE events per 1000 patients. VKA (INR 2-3) predicted 56% more DVT events (48-101 more events). Aspirin performed equivalently to LMWH. We found no significant inconsistency in the above estimates using indirect compared with direct evidence (Table 3, Table 4 for further details).
For major hemorrhage, relative to LMWH Low, direct oral Xa inhibitors demonstrated a trend towards increased hemorrhage (OR, 1.21; 95% CI, 0.79-1.90). This translates to 0.5-6 more events per 1000 patients (not statistically significant). VKA (INR 2-3) and aspirin performed equivalently relative to LMWH Low. Again, we found no significant inconsistency in the estimates using indirect compared with direct evidence.
For symptomatic DVT, relative to LMWH Low, direct oral Xa inhibitors led to 4-fold fewer events (OR, 0.25; 95% CI, 0.13-0.47), translating to 1.5-15 fewer events per 1000 patients. Small study numbers and low event rates limit the conclusions we can draw about the other options. Low numbers also prohibit our ability to make firm conclusions about the relative effectiveness of prophylaxis options for preventing non-fatal pulmonary embolism.
Relative to direct oral Xa inhibitors (direct oral Xa inhibitor as the reference option), all other strategies were inferior to direct oral Xa inhibitor, except for aspirin (Tables 5A,B ). The risk of hemorrhage was not significantly different with aspirin (OR, 0.88; 95% CI, 0.35-2.22). Small numbers of studies including aspirin limit interpretation of the performance of aspirin relative to direct oral Xa inhibitor.
In general, direct oral Xa inhibitors prevented more DVTs than LMWH Low without a relevant increase of major hemorrhage in sensitivity analysis of direct oral Xa inhibitor (Table 6 ). In subsets with non-industry sponsorship, however, the benefit of direct oral Xa inhibitors was somewhat diminished (OR, 0.76; 95% CI, 0.49-1.21). We achieved similar results comparing direct oral Xa inhibitor with LMWH Low in a traditional pairwise meta-analysis approach (OR DVT = 0.43; 95% CI, 0.34-0.60; and OR major hemorrhage = 1.19; 95% CI, 0.78-1.85).
Fondaparinux, direct thrombin inhibitors and LMWH High did not have a more favorable profile compared with LMWH Low, either because they did not significantly lower DVT or because they significantly increased the risk of hemorrhage.
Discussion
We performed a comprehensive analysis including 94 different studies of 12 prophylactic strategies for preventing VTE after THR and TKR. We found that direct oral Xa inhibitors prevented the most DVTs, including a 4-fold decrease in symptomatic DVTs compared with LMWH Low. Major hemorrhage was not significantly worse with direct oral Xa inhibitors compared with LMWH Low. Other comparators did not have a more favorable profile than LMWH Low. Small numbers prohibit firm conclusions about aspirin.
Guidelines of the American College of Chest Physicians (ACCP) published in 2012 differ from our interpretation of the available evidence [2] . They 'suggest' use of LMWH above direct oral Xa inhibitors but do not 'recommend' any one agent above the others given the lack of Grade I level evidence. To arrive at their suggestion, they first determined the rate of symptomatic VTE (symptomatic DVT and non-fatal PE) to be 9 in 1000 patients prescribed LMWH and the rate of major hemorrhage to be 12 in 1000. Then they applied the relative risk they calculated for each event and found that rivaroxaban, the most studied direct oral Xa inhibitor, prevented five more symptomatic VTE events but led to nine additional major hemorrhage events compared with LMWH, making its profile unfavorable. They did not combine brands of direct oral Xa inhibitors the way we did. In addition, they combined dosage options for low- This requirement stands in contrast to the current ISTH recommendation for defining major bleeding at the site only when bleeding resulted in reoperation hemodynamic compromise, or increase length of stay (Schulman et al. 2010 ). ¶Consistent with typical (i.e. realworld) patients undergoing total hip and knee replacement. Exclusion criteria that made study populations 'non-generalizable' included platelet counts below 100 000, any prior hemorrhagic stroke or GI bleeding (as opposed to restricting exclusion to bleeding within the past 3 months), epidural catheter use at any time (as compared with restricting to those patients with a plan for an epidural in the postoperative period when anticoagulant administration would need to begin), and any prior VTE (as opposed to restricting exclusion to VTE occurring within 3 months). **Other co-interventions included exercise and physiotherapy. † †Appropriate method, such as computer-generation or lottery cards. ‡ ‡Patients and assessor blinded to the intervention allocation. § §Blinding was appropriate and described. ¶ ¶Estimate of the withdrawal rate and a reason for each withdrawal provided. ***Intention was to treat. If unsure, not documented or stated to be per protocol, marked 'no'. molecular-weight heparin into a single prophylaxis option. This makes comparison across our analyses difficult. In addition, they performed pairwise not network analysis. We believe network meta-analysis better captures the totality of the trial data. The ACCP approach for weighting the importance of avoiding VTE and hemorrhage was different from ours. They prioritized the prevention of symptomatic VTE (a relatively stringent criterion for evaluating VTE) and major hemorrhage using the older International Society of Thrombosis and Haematosis (ISTH) definition of hemorrhage (a relatively lax criterion for evaluating major hemorrhage) [11] . The more recent surgery-specific ISTH definition of major hemorrhage is more exclusive, including only surgical-site hemorrhage that leads to significant disruption of the routine postoperative course (e.g. increased length of stay or reoperation) [16] . Based on our calculations, selecting a direct oral Xa inhibitor over LMWH Low would lead to 53-139 fewer total DVT events and 1.5-15 fewer symptomatic DVT events. Using the older, more lax definition of hemorrhage, this choice of direct oral Xa inhibitor would lead to a statistically non-significant increase of 0.5-6 more hemorrhage events. If instead we applied the more stringent, recent definition of hemorrhage, there would be no difference at all in hemorrhage rates. Readers should review these definitions when evaluating our conclusions vs. those of the ACCP guidelines. Readers should also deliberate the validity of the valuation rating exercise, which the guideline authors conducted among themselves. The exercise led them to assign an equal value to preventing symptomatic VTE and major hemorrhage (original ISTH definition). We find that long-term consequences of surgical-site In the above topology, thickness of each branch reflects number of studies directly comparing two prophylaxis options. In general, all branches contained comparisons for both DVT and hemorrhage outcome (per inclusion criteria). In a single case the branch from dynamic mechanical to aspirin did not have a bleeding outcome available which was only discovered after the study had been included and analyzed. LMWH High, low molecular-weight heparin at twice daily dosing (i.e. enoxaparin 30 mg bid); LMWH Low, low-molecular-weight heparin at standard once a day dosing (i.e. enoxaparin 40 mg or the equivalent); VKA, vitamin K antagonist; INR, International Normalized Ratio; dynamic mechanical, intermittent pneumatic compression of leg or foot; static mechanical, graduated or non-graduated compression stocking. DVT, deep vein thrombosis; Direct oral Xa inhibitor, direct oral factor Xa inhibitor; Thrombin inhibitor, oral direct thrombin inhibitor; LMWH High, low-molecular-weight heparin at twice daily dosing (i.e. enoxaparin 30 mg bid); LMWH Low, low-molecular-weight heparin at standard dose once a day dosing or the equivalent; VKA, vitamin K antagonist; INR, International Normalized Ratio; **dynamic mechanical, intermittent pneumatic compression of leg or foot; static mechanical, graduated or non-graduated compression stocking. †Includes symptomatic DVT occurring prior to surveillance or asymptomatic DVT detected at the time of surveillance imaging or if no surveillance imaging performed, outcome data abstracted based on the information available for the day closest to 11th day after surgery. ‡Each cell of the table represents an odds ratio; an asterisk* next to the odds ratio indicates a significant effect P value < 0.05. §Oral direct thrombin inhibitor.
hemorrhage (which makes up the vast majority of major hemorrhage events) are ill defined but those of VTE well established in terms of pulmonary hypertension and postthrombotic syndrome [17, 18] . Our interpretation of the available studies is also distinct from the guidelines of the American Academy of Orthopedic Surgeons (AAOS) reported in 2012 [19] . That report and its predecessor in 2007 prioritized the prevention of pulmonary embolism and the minimization of hemorrhage as main outcomes [20] . In addition, in the network analysis they performed on the secondary outcome of DVT, the AAOS guideline team members did not find that direct oral Xa inhibitors were superior to LMWH at preventing DVT. They did not isolate the LMWH High option from LMWH Low, making it difficult to compare their analysis against our own. Multiple recent studies confirm the distinctly better performance of LMWH High, justifying our analysis choice [21, 22] .
Our study also improves upon prior meta-analyses conducted in this area. Neumann et al. [23] found that rivaroxaban predicts four fewer symptomatic DVT and PE outcomes. They analyzed LMWH High and LMWH Low together. Kwok et al. [7] found that rivaroxaban is better than LMWH Low and LMWH High in preventing VTE without a significant increase in the rate of hemorrhage. Although they included indirect evidence for measuring their effects, they did not construct a full network of all regimens available and therefore cannot inform, as DVT, deep vein thrombosis; LMWH Low, low-molecular-weight heparin at standard once a day dosing or its equivalent; NA, not applicable. *Subset not reported for either outcome. †Subset not reported for bleeding outcome due to small numbers; because bleeding outcome chosen by study authors was a continuous outcome in some studies, a form we could not use for the above analysis, we have multiple instances in which we do not have a result to report for the bleeding outcome. ‡Only sponsor type reported; in the other subset, industry may have contributed but in conjunction with governmental or non-governmental organization. §Consistent with typical (i.e. real-world) patients undergoing total hip and knee replacement. These included patients with platelet counts below 100 000, non-recent hemorrhagic stroke or gastrointestinal bleeding, or epidural catheter use at any time (as compared with the period after anticoagulant prophylaxis begun), and prior VTE more than 3 months ago. ¶Appropriate method, such as computer-generation or lottery cards, used for randomization. If the randomization method was not described, it was assumed to be appropriate. Randomization based on alternate allocation of consecutive patients, date of enrollment, etc., was not considered appropriate. **Blinding was appropriate and described. † †Description of withdrawals and dropouts; estimate of the withdrawal rate and a reason for each withdrawal provided. ‡ ‡Intention was to treat. If unsure, not documented or stated to be per protocol, marked 'no'. § §Loss to follow-up was less than 20%. ¶ ¶Bleeding causing a fall in hemoglobin level of 20 g LÀ1 (1.24 mmol LÀ1) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
our analysis can, the decision making of clinicians evaluating older medications against newer options. We believe there is sufficient evidence based on the analysis we performed to narrow the choice of prophylaxis options. Direct oral Xa inhibitors have the best profile in terms of efficacy at preventing VTE and avoidance of hemorrhage. Their convenience of administration and short half-life also make this class of medication attractive. Although these new agents cost several times more than LMWH, studies have already demonstrated their cost-effectiveness [24] . Although we cannot discount aspirin, given the limited number of studies we found, there does not seem to be a compelling reason for professional societies to continue to suggest it as a prophylaxis option for the average patient undergoing THR and TKR. Aspirin could be used in very-low-risk populations, although we are unfamiliar with a robust algorithm to identify sufficiently low-risk patients. Moreover, one of the largest trials including aspirin [25] has been criticized for methodological problems which further casts doubt on the effectiveness of aspirin [2] . VKA for prophylaxis does not seem tenable either. Delays in achieving therapeutic levels, interactions with other medications, long half-life and dietary changes reduce enthusiasm for its use.
Although we performed a comprehensive analysis of the published literature, we acknowledge multiple limitations. We did not analyze the effect of pharmacologic prophylaxis combined with mechanical prophylaxis as a composite option compared with other combined prophylaxis options. We are unaware of evidence that suggests mechanical prophylaxis works better with one pharmacologic option over another. Therefore, the relative efficacy we calculated of one pharmacologic option compared with another may be applied to absolute rates of thrombosis in someone already receiving mechanical prophylaxis.
We also found a trend towards decreased benefit of direct oral Xa inhibitors in the subset of non-industry studies. High-quality non-industry studies were uncommon in our topic area. The direct oral Xa inhibitor studies we found spanned seven different individual drugs within the direct oral Xa inhibitor family, thereby mitigating the possibility of one sponsor affecting our results.
We also did not account for some design variations. These include preoperative initiation of prophylaxis vs. postoperative initiation, which is primarily relevant for LMWH. Previous investigators have failed to determine conclusively the optimal timing of prophylaxis initiation [26] . In studies in which subjects did not undergo venogram, the effect of direct oral Xa inhibitors was reduced. We believe this relates to the same potential bias introduced by industry sponsorship that used venogram-based endpoints.
We found (relative to LMWH Low) that direct oral Xa inhibitors have a favorable efficacy and safety profile, VKA has an unfavorable profile and aspirin an indeterminate profile. Our results are different from those of the ACCP because we incorporated indirect evidence (i.e. we performed a network meta-analysis) and because we analyzed LMWH Low discrete from LMWH High. Our conclusions about favorability of profiles also differ from those of the ACCP and AAOS as we placed a higher value on prevention of asymptomatic and symptomatic DVT and less value on major hemorrhage that does not result in disruption of care (ISTH 2005 definition) and has ill-defined sequelae.
Clinicians agreeing with our approach should limit selection of prophylaxis options to those we identified with better profiles.
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